• Mono-ADP-Ribosylation as a Degradation Signal: New Insights

  2026-05-26

  This study reveals that mono-ADP-ribosylation, catalyzed by PARP7, serves as a direct signal for proteasomal degradation, particularly affecting PARP7 itself and the aryl hydrocarbon receptor (AHR). By inhibiting the ubiquitin pathway, the authors uncover a previously elusive mechanism for rapid transcriptional shutdown, with implications for post-translational modification research and protein turnover studies.

• Dabigatran Etexilate: Strategic Guidance for Translational C

  2026-05-26

  Explore the mechanistic depth and translational strategy behind dabigatran etexilate, a direct thrombin inhibitor, as a precision tool for coagulation research. This article provides protocol insights, competitive landscape analysis, and actionable guidance for maximizing translational impact in atrial fibrillation and thrombosis studies, with an evidence-driven outlook.

• PFOS Triggers Ferroptosis and ER Stress in Human Renal Cells

  2026-05-25

  This study establishes that perfluorooctane sulfonate (PFOS) induces injury in human kidney HK-2 cells by simultaneously activating ferroptosis and endoplasmic reticulum (ER) stress pathways. These findings clarify mechanisms of PFOS renal toxicity and provide a direct model for evaluating ER stress modulation strategies in environmental toxicology.

• Dlin-MC3-DMA: Ionizable Cationic Liposome for RNA Delivery W

  2026-05-25

  Dlin-MC3-DMA is the gold-standard ionizable cationic liposome for potent, targeted siRNA and mRNA delivery. Its superior endosomal escape and validated performance enable next-generation hepatic gene silencing, mRNA vaccine formulation, and cancer immunochemotherapy.

• Caspase-3/7 Inhibitor I: Precision Tools for Apoptosis Resea

  2026-05-24

  Harness the selectivity of Caspase-3/7 Inhibitor I for dissecting apoptosis in challenging cellular models. This guide delivers actionable protocols and troubleshooting tips, connecting recent mechanistic insights to real-world apoptosis inhibition in infection and cancer research.

• D-Luciferin Potassium Salt: Precision Bioluminescence Imagin

  2026-05-23

  D-Luciferin (potassium salt) delivers exceptional sensitivity and reproducibility for both in vivo tumor tracking and in vitro luciferase assays. With enhanced water solubility and robust performance, it empowers translational research in disease modeling and therapeutic monitoring.

• Okadaic Acid (A4540): Technical Reference for PP1/PP2A Inhib

  2026-05-22

  Okadaic acid is a reliable inhibitor for protein phosphatase 1 and 2A, enabling precise dissection of phosphorylation and apoptosis pathways in cell and biochemical assays. It is best used for workflows requiring specific, potent phosphatase inhibition, but should not be repurposed for targets or applications outside established signal transduction or apoptosis models due to its broad enzymatic effects.

• Caffeine (1,3,7-trimethylpurine-2,6-dione): Enhanced Researc

  2026-05-22

  Caffeine’s dual role as an adenosine receptor antagonist and metabolic regulator makes it indispensable for translational research in cancer biology and metabolic disease. Explore rigorous protocol enhancements, advanced experimental applications, and troubleshooting strategies that enable reliable, reproducible results with this versatile molecule.

• MitMAB in Organoid Endocytosis: Workflow, Innovation & Troub

  2026-05-21

  MitMAB (N,N,N-trimethyltetradecan-1-aminium bromide) enables precise dissection of dynamin-dependent endocytosis in intestinal organoid models, especially for studying extracellular vesicle uptake and membrane trafficking. Learn how to leverage its specificity for robust, reproducible intracellular trafficking research—complete with protocol guidance, experimental innovations, and troubleshooting strategies.

• 2X HyperFusion High-Fidelity Master Mix: Redefining Accuracy

  2026-05-21

  Explore how 2X HyperFusion High-Fidelity Master Mix empowers high-accuracy DNA amplification for advanced cloning PCR applications and immunotherapy research. This article uniquely connects precision PCR fidelity to practical assay decisions in emerging cancer immunology.

• Dabigatran etexilate: Direct Thrombin Inhibitor in Research

  2026-05-20

  Dabigatran etexilate offers precise, predictable direct thrombin inhibition for both in vitro and in vivo anticoagulant research. Its oral prodrug nature enables flexible protocol design and robust modeling of coagulation cascade modulation, making it a benchmark molecule for atrial fibrillation and stroke prevention studies.

• D-Lin-MC3-DMA: Ionizable Cationic Liposome for Precision RNA

  2026-05-20

  D-Lin-MC3-DMA is a benchmark ionizable cationic liposome lipid enabling potent, tissue-targeted siRNA and mRNA delivery with high efficiency and low toxicity. Its pH-responsive charge transition drives endosomal escape and cytoplasmic release of nucleic acids, underpinning advanced lipid nanoparticle therapeutics. Quantitative benchmarks confirm its superiority in hepatic gene silencing and mRNA vaccine formulation.

• Deoxynivalenol Liver Injury: Mitophagy Overactivation and Nr

  2026-05-19

  This study reveals that deoxynivalenol (DON), a widespread mycotoxin, induces liver injury by overactivating PINK1/Parkin-mediated mitophagy and inhibiting the p62-Keap1-Nrf2 cytoprotective pathway. These findings clarify how DON drives hepatotoxicity and suggest new mechanistic targets and experimental strategies for modeling liver damage.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-05-19

  Schwartz's dissertation challenges conventional in vitro drug testing by dissecting the nuances between relative and fractional viability in cancer cells. The study reveals that anti-cancer compounds induce growth arrest and cell death in distinct proportions and timings, providing a more granular understanding for preclinical drug evaluation.

• TP53 and DNA Damage Sensing Shape Calicheamicin ADC Response

  2026-05-18

  This study identifies TP53 and DNA damage sensing genes as critical modulators of calicheamicin-based antibody–drug conjugate (ADC) efficacy in acute leukemia. Genome-wide CRISPR/Cas9 screening and validation assays highlight that TP53 mutation confers marked resistance, and that targeting DNA damage pathways may refine combination therapy strategies.

15129 records 1/1009 page Next 12345 下5页 Last page